‘ United States Steel (X) Continues to Show Positive Momentum and Resilience in the Steel Industry\n\nUnited States Steel (X) has been making headlines in the market recently, with its stock price experiencing a surge after reports of multiple acquisition bids valuing the company at $40 per share. This news comes after a recent report revealed that the steel producer’s plane was spotted in Charlotte, N.C., further fueling speculation of a potential acquisition.\n\nAs Warren Buffett famously said, “Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace.” This statement holds true for United States Steel, as its stock price has not fully reflected its improving financials in recent years. In fact, the company has gone from a loss to profitability in the past three years, which is generally seen as a positive sign. The stock price has not fully reflected this improvement.\n\nUnited States Steel has still managed to outperform the market return of 14% with a 96% increase in its stock price over the past three years. This is a testament to the company’s resilience and potential for growth in the steel industry. In the past year alone, the stock price has shown a 42% increase, including dividends. This positive momentum is further supported by the company’s strengthening balance sheet and improving earnings.\n\nThe company’s total shareholder return over the past three years is 100%, exceeding the share price return. This can be attributed to the dividends paid by the company.\n\n United States Steel (X) continues to show positive momentum and resilience in the steel industry.’

'Shattuck Labs, Inc. Reports Positive Initial Data from Phase 1AB Trial of SL-172154 in Frontline HR-MDS and TP53m AML Patients\n\nShattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company, has announced promising initial results from its ongoing Phase 1AB clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline HR-MDS and TP53m AML patients. These results build on the complete dose-escalation data presented at the 65th ASH Annual Meeting on December 11, 2023.\n\nDr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck, stated, "We are pleased to share the initial efficacy data from our dose-expansion cohorts, which demonstrate the potential of SL-172154 beyond what is expected of AZA alone. In the dose-escalation study, we saw a monotherapy response in a heavily pre-treated RR TP53m AML patient, allowing the patient to receive a stem cell transplant and remain disease-free. In the frontline cohorts, we have already observed a promising rate of complete responses in both HR-MDS and TP53m AML patients, and we expect this rate to continue to improve as more data becomes available."\n\nThe Phase 1AB trial enrolled 14 frontline TP53m AML patients and 22 frontline HR-MDS patients. Initial enrollment was completed in mid-2023, and the study is ongoing. Preliminary data suggest that SL-172154 has an acceptable safety and tolerability profile in combination with AZA.\n\nShattuck will host a conference call and webcast today, December 13, 2023 at 8:00 a.m. ET to discuss the initial data from the Phase 1AB trial. The company has also amended both studies to increase the sample size and plans to provide another update by mid-year 2024.\n\nIn a Shattuck Labs, Inc. has reported positive initial data from its Phase 1AB trial of SL-172154 in frontline HR-MDS and TP53m AML patients.'